At minimum, they should engage in compliance risks; financial opportunities; key advocacy efforts; and program resources, structure, and value.
Jacob Thompson, PharmD, MS, 340B ACE
Advertisement
Articles by Jacob Thompson, PharmD, MS, 340B ACE
Advertisement
Latest Updated Articles
Partner With 340B Executive StakeholdersPublished: May 26th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Addressing Drug Resistance in Lung Cancer
2
From Mutation to Medicine: Targeted Therapies in Lung Cancer
3
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
4
TAR-200 Intravesical System Demonstrates Sustained Bladder Exposure in BCG-Unresponsive NMIBC
5
